HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.
Share
If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
Why is Hims & Hers being Investigated?
Hims & Hers is a telehealth company that provides consumers access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' through which Hims & Hers would sell Novo Nordisk's popular weight loss drug Wegovy.
The Stock Declines as the Truth is Revealed
On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in 'deceptive marketing' and the illegal 'selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' On this news, the price of Hims & Hers stock fell $22.25 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
What Can You Do?
If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
https://www.bfalaw.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Earnings To Watch: Lindsay (LNN) Reports Q2 Results Tomorrow
Agricultural and farm machinery company Lindsay (NYSE:LNN) will be announcing earnings results this Thursday morning. Here's what investors should know. Lindsay beat analysts' revenue expectations by 4% last quarter, reporting revenues of $187.1 million, up 23.5% year on year. It was an incredible quarter for the company, with a solid beat of analysts' organic revenue estimates and an impressive beat of analysts' EPS estimates. Is Lindsay a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lindsay's revenue to grow 16.4% year on year to $162 million, a reversal from the 15.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lindsay has missed Wall Street's revenue estimates four times over the last two years. With Lindsay being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for heavy machinery stocks. However, there has been positive investor sentiment in the segment, with share prices up 2.9% on average over the last month. Lindsay is down 1.1% during the same time and is heading into earnings with an average analyst price target of $139 (compared to the current share price of $138.22). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Reasons to Like FVRR (and 1 Not So Much)
Over the past six months, Fiverr's stock price fell to $29.31. Shareholders have lost 12.1% of their capital, disappointing when considering the S&P 500 was flat. This was partly due to its softer quarterly results and might have investors contemplating their next move. Following the drawdown, is now a good time to buy FVRR? Find out in our full research report, it's free. Based in Tel Aviv, Fiverr (NYSE:FVRR) operates a fixed price global freelance marketplace for digital services. Average revenue per buyer (ARPB) is a critical metric to track because it measures how much the company earns in transaction fees from each buyer. This number also informs us about Fiverr's take rate, which represents its pricing leverage over the ecosystem, or "cut" from each transaction. Fiverr's ARPB growth has been exceptional over the last two years, averaging 17.4%. Although its active buyers shrank during this time, the company's ability to successfully increase monetization demonstrates its platform's value for existing buyers. We track the change in earnings per share (EPS) because it highlights whether a company's growth is profitable. Fiverr's EPS grew at an astounding 52.1% compounded annual growth rate over the last three years, higher than its 8.6% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. As a gig economy marketplace, Fiverr generates revenue growth by expanding the number of services on its platform (e.g. rides, deliveries, freelance jobs) and raising the commission fee from each service provided. Fiverr struggled with new customer acquisition over the last two years as its active buyers have declined by 6.6% annually to 3.54 million in the latest quarter. This performance isn't ideal because internet usage is secular, meaning there are typically unaddressed market opportunities. If Fiverr wants to accelerate growth, it likely needs to enhance the appeal of its current offerings or innovate with new products. Fiverr's positive characteristics outweigh the negatives. With the recent decline, the stock trades at 12.3× forward EV/EBITDA (or $29.31 per share). Is now a good time to initiate a position? See for yourself in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
an hour ago
- Business Insider
Needham Downgrades Hims & Hers Stock (HIMS) on Novo Nordisk Fiasco. Wall Street Sees Legal Risks
On Monday, Hims & Hers (HIMS) stock plunged about 35% after Danish drugmaker Novo Nordisk (NVO) ended its partnership with HIMS, accusing it of illegally selling copycats of its weight-loss drug Wegovy (semaglutide). In reaction, Needham analyst Ryan MacDonald downgraded Hims & Hers stock to Hold from Buy and removed the $65 price target. Needham also removed HIMS stock from its Conviction List. Other Wall Street analysts also weighed in on HIMS' fallout with Novo Nordisk, noting legal risks. Confident Investing Starts Here: Needham Downgrades HIMS Stock to Hold MacDonald downgraded HIMS stock due to the termination of the key deal with Novo Nordisk and fears of a potential lawsuit. The 4-star analyst thinks that Hims & Hers will likely continue to offer personalized GLP-1s (drugs for weight loss and diabetes) under its interpretation of section 503A (outlines the conditions under which compounded drug products are exempt from certain FDA requirements). This, he believes, brings back the risk of litigation or regulatory action. He added that HIMS is now at a competitive disadvantage, given that both Eli Lilly (LLY) and Novo Nordisk maintain partnerships with its rivals. MacDonald believes that HIMS stock could be range-bound over the near term, as the legality of HIMS' personalization practices is determined. Other Analysts Weigh in on HIMS-NOVO Fallout Meanwhile, Morgan Stanley analyst Craig Hettenbach reiterated a Hold rating on Hims & Hers stock with a price target of $40. Hettenbach estimates that 'personalized' compounded semaglutide doses comprise over 50% of HIMS' target of $725 million in weight loss revenue for 2025. The 4-star analyst thinks that the abrupt termination of the deal could renew concerns over litigation. Further, Truist Securities analyst Jailendra Singh reiterated a Hold rating on HIMS stock with a price target of $45. Singh also believes that with the termination of the partnership, the litigation risk is 'back on the table.' He added that a potential litigation could drag on for 18-24 months and remain an overhang on HIMS stock. That said, Singh does not believe that branded Wegovy was driving any significant subscriber growth or revenue for HIMS, likely resulting in Novo's decision to end the collaboration. However, Singh thinks that HIMS was perhaps gaining from the 'credibility' or increased consumer traffic to its platforms due to ads for the branded Wegovy. Consequently, Singh expects the end of the deal to trigger a decline in traffic, adversely impacting HIMS' compounding business. Finally, Bank of America analyst Allen Lutz reiterated a Sell rating on Hims & Hers stock with a price target of $28, saying that the end of the deal was a 'clear negative.' Lutz sees a high likelihood of Novo Nordisk pursuing litigation. The 4-star analyst noted that HIMS generated $230 million of compounded semaglutide revenue in Q1 2025 and is expected to deliver about $170 million in Q2. He estimates that Wegovy represented a low single-digit percentage of GLP-1s (~2%) orders in Q2, implying that the loss of the partnership won't result in any notable change to revenue. That said, Lutz noted a slowdown in HIMS' core business, which presents a significant risk to consensus estimates in the second half of 2025 and 2026. Blame Game On Novo Nordisk blamed Hims & Hers for 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy,' putting patient safety at risk. Meanwhile, responding to the termination of the deal, Hims & Hers CEO Andrew Dudum stated that the company is 'disappointed to see Novo Nordisk management misleading the public.' Dudum accused Novo Nordisk's commercial team of increasing pressure on Hims & Hers to control clinical standards and move patients to Wegovy regardless of whether it was clinically best for patients. He added that HIMS refuses to be 'strong-armed' by any anticompetitive demand of any pharmaceutical company that impacts the independent decision-making of providers and limits patient choice. Is HIMS a Good Stock to Buy? Overall, Wall Street is sidelined on HIMS stock, with a Hold consensus rating based on one Buy, eight Holds, and two Sell recommendations. The average HIMS stock price target of $39.80 indicates about 5.2% upside potential.
